TAVALISSE effectively increases platelet counts in adults with chronic ITP who have not responded to prior therapies.

Clinical Efficacy of TAVALISSE in Chronic ITP

TAVALISSE has demonstrated efficacy in elevating platelet counts in adult patients with chronic immune thrombocytopenia (ITP) refractory to previous treatments. Clinical trials showed a statistically significant proportion of patients achieving stable platelet responses (≥50 × 10⁹/L) compared to placebo, reducing the risk of bleeding events. The therapeutic benefit is most pronounced in patients with persistent or chronic ITP, including those with prior splenectomy or thrombopoietin receptor agonist exposure. The drug’s mechanism targets SYK-mediated pathways, thereby mitigating antibody-driven platelet destruction.